Breaking News

Aardvark Therapeutics Announces $85M Series C Financing

Will use the proceeds from the financing to advance the regulatory approval of its lead asset, ARD-101.

Author Image

By: Charlie Sternberg

Associate Editor

Aardvark Therapeutics Inc. has announced an $85 million oversubscribed Series C financing led by Decheng Capital, with participation from Cormorant Asset Management, Surveyor Capital, SymBiosis, Tetragon Financial Group, Walleye Capital, Laurion Capital Management, LG Technology Ventures, Cantor Fitzgerald & Co., Silver Arc Private Capital, The Prader-Willi Syndrome Association – USA, and existing investors, including Vickers Venture Partners and the Foundation for Prader-Willi Research.   ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters